Hepatitis Newsline


Published April 19, 2013 Reuters
Blood tests conducted on patients treated at an Oklahoma oral surgery practice that has been closed over health concerns show that 57 have hepatitis C, three have hepatitis B and as many as three have HIV, the virus than can lead to AIDS, officials said on Thursday.

By KRISTEN WYATT, Associated Press – Wed Jan 19, 4:31 pm ET
DENVER – Some Colorado lawmakers say their state should be the first one where people become organ donors by default, even though other states' efforts have been halted by worries about making such a personal decision automatic.

By Kelly Luker
There could be worse things than having a chronic, life-threatening, stigmatizing virus. No, really.
This is not the beginning of a tell-all memoir, but merely a bit of history that is relevant to a here-and-now situation that found its roots in that decade.

News and views regarding liver disease.

News about the Hepatitis C virus
Our site-wide left sidebar will always feature three stories about Hepatitis C that catch our interest.
Use the News page to look for more about liver disease in general, or to to search for a specific topic you may need to know about as you or a loved one lives with and recovers from Hep C.
Jury: HMO liable for $24 million in Las Vegas hepatitis C outbreak Plaintiffs to seek $1 billion in punitive damages

Jury: HMO liable for $24 million in Las Vegas hepatitis C outbreak Plaintiffs to seek $1 billion in punitive damages

LAS VEGAS — A Nevada state court jury found the state's largest health management organization liable Thursday for $24 million in compensatory damages to three plaintiffs in a negligence lawsuit stemming from a Las Vegas hepatitis C outbreak that lawyers called the largest in U.S. history.

The hepatitis outbreak became public in early 2008, when the Southern Nevada Health District in Las Vegas notified more than 50,000 Desai patients to get tested for blood-borne diseases including AIDS.
Health investigators later traced hepatitis C infections of nine people to procedures conducted in 2007 at endoscopy clinics owned by Desai. Although investigators reported finding hepatitis C in another 105 patients, the cases weren't conclusively linked to Desai clinics.
Eglet and Kemp also won hundreds of millions of dollars in civil judgments in 2011 against pharmaceutical companies they blamed for supplying recklessly large vials of the powerful anesthetic propofol to Desai clinics. Jurors were told in that case that the large vials were unsafely reused from patient to patient.

Desai and his clinics reached undisclosed settlements with plaintiffs before trial in those cases.

Plaintiffs Bonnie Brunson, 70, and her husband, Carl, who is 72, clasped hands tightly and she sobbed quietly as the verdict was read, ending the liability phase of what has been a six-week civil trial in Clark County District Court. By Ken Ritter, Associated Press

MORE >>
Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

PRESS RELEASE: Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS` investigational NS5A replication complex inhibitor daclatasvir-

-Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013-

-Study in people with genotypes 1, 2 and 3 hepatitis C, including people with cirrhosis, planned for second half of 2013- CAMBRIDGE, Mass.--(Business Wire)--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company (NYSE: BMY) to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex`s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Bristol-Myers Squibb`s NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in treatment-naïve people with genotype 1 HCV infection planned for the second quarter of 2013. Vertex plans to begin a subsequent study in treatment-naïve people infected with genotype 1, 2 or 3 HCV, including those with cirrhosis, in the second half of 2013, pending data from the initial study.

"With more than 170 million people infected worldwide, there is a critical need for new hepatitis C medicines that can offer people simpler and more tolerable treatment regimens that provide high cure rates," said Robert Kauffman, M.D., Ph.D., Senior Vice President and Chief Medical Officer at Vertex. "These studies with daclatasvir will provide the first opportunity to evaluate VX-135 as part of all-oral regimens in people with multiple hepatitis C genotypes and in people with cirrhosis."

MORE >>
Gilead Quad HIV drug causes fewer side effects

Exclusive Interview with Gregg Allman on his new book, 'My Cross to Bear'

Gregg Allman's musical journey, as told in his new book, "My Cross to Bear," is a gut-wrenching, brutally honest self-reflection of a true rock-and-roll survivor.
The moving narration chronicles his long struggle with substance abuse, life in one of rock's legendary Allman Brothers band and the tragic deaths of his brother, Duane, and the group's bassist Berry Oakley. By Paty Elias

MORE >>
Gilead Quad HIV drug causes fewer side effects

Gilead Quad HIV drug causes fewer side effects

Full details from a pivotal trial of Gilead Sciences Inc experimental Quad HIV pill show that it caused fewer adverse side effects than the company's current three-drug pill, Atripla. SEATTLE (Reuters)
MORE >>
Hepatitis C-related deaths outpace HIV deaths, study says

Hepatitis C-related deaths outpace HIV deaths, study says

Hepatitis C mortality rates surpassed HIV mortality rates in the United States in 2007, researchers said Monday.
By Eryn Brown, Los Angeles Times / For the Booster Shots blog February 21, 2012, 4:03 p.m.

MORE >>
Hepatitis C death rates rise, 1 in 33 baby boomers has disease

Hepatitis C death rates rise, 1 in 33 baby boomers has disease

(CBS/AP) Hepatitis C deaths are on the rise, according to a new report from the Centers for Disease Control and Prevention. The report found baby boomers are especially at risk because they account for two-thirds of all hepatitis C cases.
By AP / DAN GELSTON AND TIM DAHLBERG Monday, Nov. 07, 2011

MORE >>
CDC chief picks 6 'winnable battles' in health

During HCV Treatment: lower levels of ribavirin found in African American patients than non-African American Pharmacy Student's Drug Model Could Mean Better Outcomes for Hepatitis C Patients.
University of Maryland School of Pharmacy researchers have developed a mathematical model for choosing an appropriate dosage of the hepatitis medications for individual patients. The work helps explain why African American patients tend to not respond as well to the drugs as other patients. For the work, student researcher Runyan Jin, MD, PhD, won the best student research award and a $1,000 prize for her work at the 2010 American College of Clinical Pharmacology (ACCP) scientific meeting. Her project involved analyzing 900 blood samples from 400 patients enrolled in a multi-center trial to determine why hepatitis therapy works for some patients, but not others.

MORE >>
Hepatitis C and Weill Cornell Medical Center

The transplant hepatology fellowship at The Mount Sinai Medical Center in New York City offers year-long advanced clinical training to applicants who have already completed a gastroenterology fellowship.
Mount Sinai's transplant hepatology fellowship was the first to be ACGME-approved in the Northeast and remains the largest such fellowship in the United States.
The program was reaccredited in 2010 by ACGME for the maximum five-and-a-half years.

MORE >>

Natalie Cole and Hepatitis C

(CBS) You may know Natalie Cole as a gorgeous, Grammy-winning singer, but as she reveals in her gripping new memoir, she's also a former junkie and double organ transplant recipient.
In her twenties, Cole was addicted to heroin. Then she got clean and sober. Twenty-five years later, in early 2008, she discovered she had hepatitis C.
"Hep C" is a life-threatening liver disease that's spread through contact with infected blood during sex, through sharing needles, and from mother to baby during childbirth. There is no vaccine.
Cole's doctor suggested that she may have caught the virus when she was sharing needles during her wild days in New York, and that it had remained dormant in her body for over two decades.

MORE >>

Hepatitis C Resources

Let Billy Drop guide you through our resource for the Hepatitis C community.

Let Billy Drop guide you while exploring the Hepatitis Community experience.

complimentary care for Hepatitis C
Information for health care professionals:
The American Liver Foundation is committed to supporting progress in liver disease treatment and assisting those who work in the field of hepatology. Whether you are a researcher pursuing a liver-related project or a physician seeking materials for your patients, we can help.
MORE >>
Billy Drop and Hepatitis C education Then click here for webmaster.
Let Billy Drop guide you through our resource for the Hepatitis C community.

Buy a shirt, a hat, a sticker or a dvd to help us keep you informed.

Use PayPal secure gateway >>